For the quarter ending 2026-03-31, SGMO made $1,442K in revenue. -$30,995K in net income. Net profit margin of -2149.45%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenues | 1,442 | 14,228 | 581 | 18,306 |
| Research and development | 26,570 | 31,438 | 28,142 | 27,084 |
| Impairment of long-lived assets | - | 13,235 | 0 | 0 |
| General and administrative | 6,818 | 7,758 | 7,992 | 9,077 |
| Total operating expenses | 33,388 | 52,431 | 36,134 | 36,161 |
| Loss from operations | -31,946 | -38,203 | -35,553 | -17,855 |
| Interest income | 300 | 252 | 355 | 386 |
| Other income (expense), net | 651 | -21 | 107 | -2,490 |
| Loss before income taxes | -30,995 | -37,972 | -35,091 | -19,959 |
| Income tax expense | 0 | -553 | -161 | 27 |
| Net loss | - | -37,419 | -34,930 | -19,986 |
| Net income allocated to participating securities | - | - | 0 | - |
| Net loss | -30,995 | - | -34,930 | - |
| Basic EPS | -0.08 | -0.11 | -0.11 | -0.08 |
| Diluted EPS | -0.08 | -0.11 | -0.11 | -0.08 |
| Basic Average Shares | 389,616,000 | 339,285,000 | 304,268,000 | 256,950,000 |
| Diluted Average Shares | 389,616,000 | 339,285,000 | 304,268,000 | 256,950,000 |
SANGAMO THERAPEUTICS, INC (SGMO)
SANGAMO THERAPEUTICS, INC (SGMO)